(Q46646334)

23 December 2017

title

The adjuvant effect of levamisole on killed viral vaccines (English)

1 reference

23 December 2017

1 reference

Youmin Kang

1

1 reference

23 December 2017

Huali Jin

2

1 reference

23 December 2017

Guoxing Zheng

3

1 reference

23 December 2017

Qifa Xie

4

1 reference

23 December 2017

Jiangmei Yin

5

1 reference

23 December 2017

Yang Yu

6

1 reference

23 December 2017

Chong Xiao

7

1 reference

23 December 2017

Xiaoying Zhang

8

1 reference

23 December 2017

Aoshuang Chen

9

1 reference

23 December 2017

Bin Wang

10

1 reference

23 December 2017

language of work or name

English

0 references

publication date

25 July 2005

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

48-49

1 reference

23 December 2017

page(s)

5543-5550

1 reference

23 December 2017

Recent developments in adjuvants for vaccines against infectious diseases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Adjuvants--a balance between toxicity and adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Developments in foot-and-mouth disease vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Overview of vaccine adjuvants: present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

The general immunopharmacology of levamisole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

The induction of interferon by levamisole in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Restoration of T-cell function in aged mice with long-term administration of levamisole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Effect of chemical adjuvants on DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Carriers of foot-and-mouth disease virus: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Isolation of a Lelystad virus-like agent from British pigs and scanning electron microscopy of infected macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

The suppressors of cytokine signalling (SOCS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Suppressors of cytokine signaling and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

New developments in adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Recent advances in veterinary vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Structure and evolution of the extended B7 family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.017

10.1016/J.VACCINE.2005.07.017

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

release_qnr465ozj5cwdhmoybcy7chgwy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qnr465ozj5cwdhmoybcy7chgwy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 December 2017